The Tomosynthesis Mammographic Imaging Screening Trial (TMIST) has now enrolled more than 25,000 patients and secured 105 (94 active) of the planned 150 study sites. This represents a 500 percent increase in patients and 100 percent rise in sites since January 2019. However, more patients and sites are needed for TMIST - the largest randomized, controlled breast cancer screening trial ever conducted.
TMIST seeks to determine if routine breast cancer screening with digital breast tomosynthesis (DBT) outpaces two-dimensional (2D) digital mammography at reducing advanced breast cancer development in the breast cancer screening population. TMIST will also create the world’s largest breast cancer biorepository.
National Institutes of Health funding supports site participation TMIST, outlined in this video, that have attracted interest from non-academic, community-based women’s health services, large health systems and freestanding radiology sites alike.
Medical imaging providers can visit acr.org/TMIST to find out how and why to take part in this landmark study.
Email TMIST@acr.org with any questions regarding TMIST.